AnalystsInsight

Craig Hettenbach (Morgan Stanley): Analyst Track Record and Price‑Target Accuracy

How often Craig Hettenbach’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,265 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Craig Hettenbach ranks #859 of 1,121 analysts in Exent’s scoring (4.7★).
  • 52.8% of price targets were reached over 7 years, versus 53.6% for the average analyst.
  • Median time to reach a target: 73 days; 58.8% of calls were up 12 months later.
  • Most‑covered stocks: HIMS, OMDA, HNGE, DOCS.
  • Free on Exent: Craig Hettenbach’s full record, with ratings 3 days after publication.

Craig Hettenbach’s track record at a glance

Craig Hettenbach of Morgan Stanley ranks #859 of the 1,121 analysts Exent scores, with a 4.7★ rating and a focus on technology. Over a 7‑year lookback, 52.8% of Craig’s price targets were reached, 0.8 points below the 53.6% average across all analysts.

MetricCraig HettenbachAll analysts
Price‑target hit rate52.8%53.6%
Median days to hit target73 days91 days
Calls up after 12 months58.8%64.6%
Median 12‑month return of calls+11.0%+13.4%
Hit rate, last 2 years55.8%—
Average worst drop after a call−26.7%—
Ratings in the sample1,265—
Stocks covered32—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetCraig Hettenbach
Under 30 days23.8%
30–90 days38.1%
90–180 days22.4%
Over 180 days15.7%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Craig Hettenbach covers most

StockRatings in the sample
HIMS62
OMDA49
HNGE45
DOCS40
VEEV33
THC26
LFST20
GDRX19

In the past year Craig’s ratings were 44% Buy, 50% Hold and 6% Sell.

Craig Hettenbach’s latest ratings

DateStockActionRatingPrice target
Oct 14, 2026DOCSMaintained: BuyBuy$35.00
Oct 13, 2026OMDAReiterated: BuyBuy$30.00
Oct 13, 2026OMDAMaintained: BuyBuy$30.00
Oct 12, 2026THCRated: BuyBuy$274.00
Oct 12, 2026HNGEReiterated: BuyBuy$117.00
Oct 12, 2026THCReiterated: BuyBuy$274.00
Oct 12, 2026HNGEMaintained: BuyBuy$117.00
Sep 28, 2026OMDAMaintained: BuyBuy$30.00
Sep 28, 2026OMDAReiterated: BuyBuy$30.00
Sep 18, 2026VEEVRated: HoldHold$275.00
Sep 18, 2026DOCSRated: BuyBuy$35.00
Sep 17, 2026CERTReiterated: HoldHold$9.00
  • Oct 14, 2026
    Stock
    DOCS
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $35.00
  • Oct 13, 2026
    Stock
    OMDA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $30.00
  • Oct 13, 2026
    Stock
    OMDA
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $30.00
  • Oct 12, 2026
    Stock
    THC
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $274.00
  • Oct 12, 2026
    Stock
    HNGE
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $117.00
  • Oct 12, 2026
    Stock
    THC
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $274.00
  • Oct 12, 2026
    Stock
    HNGE
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $117.00
  • Sep 28, 2026
    Stock
    OMDA
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $30.00
  • Sep 28, 2026
    Stock
    OMDA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $30.00
  • Sep 18, 2026
    Stock
    VEEV
    Action
    Rated: Hold
    Rating
    Hold
    Price target
    $275.00
  • Sep 18, 2026
    Stock
    DOCS
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $35.00
  • Sep 17, 2026
    Stock
    CERT
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $9.00

Craig’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Oct 20, 2026; ranking updated Oct 21, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Craig Hettenbach’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Craig Hettenbach ranks #859 of 1,121 with a 4.7★ rating. 52.8% of price targets were reached over a 7-year lookback (all analysts: 53.6%), and 58.8% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Craig Hettenbach’s success rate is 60.6% by the ranking source and 52.8% by Exent’s price-target hit-rate backtest, with a median of 73 days to reach a target.

Craig Hettenbach (Morgan Stanley) covers 32 stocks, mostly in technology. The most frequently rated are HIMS, OMDA, HNGE, DOCS, VEEV.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.